Top

Published in:

01-01-2015 | Original Article

Plasma pharmacokinetics and tissue and brain distribution of cisplatin in musk shrews

Authors: Julie L. Eiseman, Jan H. Beumer, Lora H. Rigatti, Sandra Strychor, Kelly Meyers, Samuel Dienel, Charles C. Horn

Published in: Cancer Chemotherapy and Pharmacology | Issue 1/2015

Abstract

Purpose

Cisplatin induces nausea and emesis, even with antiemetic supportive care. To assess platinum exposure, which could activate nausea and emesis, we quantitated platinum in the brain and various organs, and hindbrain and spinal cord substance P, a key neuropeptide for the neuronal signaling of nausea and emesis.

Methods

Musk shrews, a model species for nausea and emesis research, were dosed intraperitoneally with 20 mg/kg cisplatin and euthanized at up to 72 h after injection. Concentrations of platinum were quantitated in plasma ultrafiltrate, plasma, lung, kidney, combined forebrain and midbrain, hindbrain, and spinal cord by flameless atomic absorption spectrometry. Hindbrains and spinal cords were analyzed for substance P by immunohistochemistry after injection of 20 or 30 mg/kg.

Results

Plasma ultrafilterable platinum concentrations decreased rapidly till 60 min after dosing and then more slowly by 24 h. The concentrations of total platinum in both the fore- and midbrain and the hindbrain were similar at all time points and were at least 20-fold lower than plasma total platinum concentrations. There were no significant changes in substance P immunoreactivity after cisplatin dosing. Histology revealed damage to the renal cortex by 72 h after injection of cisplatin.

Conclusions

This is the first study to examine platinum concentrations in musk shrews after administration of cisplatin and delineate substance P immunohistochemical staining in the hindbrain and spinal cord of this species. The platinum concentrations detected in the brain could potentially contribute to the neurological side effects of cisplatin, such as nausea and emesis.

Roila F, Herrstedt J, Aapro M, Gralla RJ, Einhorn LH, Ballatori E, Bria E, Clark-Snow RA, Espersen BT, Feyer P, Grunberg SM, Hesketh PJ, Jordan K, Kris MG, Maranzano E, Molassiotis A, Morrow G, Olver I, Rapoport BL, Rittenberg C, Saito M, Tonato M, Warr D (2010) Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol 21(Suppl 5):v232–v243PubMedCrossRef

Hesketh PJ, Grunberg SM, Herrstedt J, de Wit R, Gralla RJ, Carides AD, Taylor A, Evans JK, Horgan KJ (2006) Combined data from two phase III trials of the NK1 antagonist aprepitant plus a 5HT 3 antagonist and a corticosteroid for prevention of chemotherapy-induced nausea and vomiting: effect of gender on treatment response. Support Care Cancer 14(4):354–360PubMedCrossRef

Kris MG, Cubeddu LX, Gralla RJ, Cupissol D, Tyson LB, Venkatraman E, Homesley HD (1996) Are more antiemetic trials with a placebo necessary? Report of patient data from randomized trials of placebo antiemetics with cisplatin. Cancer 78(10):2193–2198PubMedCrossRef

Martin M (1996) The severity and pattern of emesis following different cytotoxic agents. Oncology 53(Suppl 1):26–31PubMedCrossRef

Hesketh PJ, Van Belle S, Aapro M, Tattersall FD, Naylor RJ, Hargreaves R, Carides AD, Evans JK, Horgan KJ (2003) Differential involvement of neurotransmitters through the time course of cisplatin-induced emesis as revealed by therapy with specific receptor antagonists. Eur J Cancer 39(8):1074–1080PubMedCrossRef

Albany C, Brames MJ, Fausel C, Johnson CS, Picus J, Einhorn LH (2012) Randomized, double-blind, placebo-controlled, phase iii cross-over study evaluating the oral neurokinin-1 antagonist aprepitant in combination with a 5HT3 receptor antagonist and dexamethasone in patients with germ cell tumors receiving 5-day cisplatin combination chemotherapy regimens: a hoosier oncology group study. J Clin Oncol 30(32):3938–4003CrossRef

Rudd JA, Andrews PLR (2005) Mechanisms of acute, delayed, and anticipatory emesis induced by anticancer therapies. In: Hesketh PJ (ed) Management of nausea and vomiting in cancer and cancer treatment. Jones and Bartlett, Sudbury, pp 15–65

Minami M, Endo T, Hirafuji M, Hamaue N, Liu Y, Hiroshige T, Nemoto M, Saito H, Yoshioka M (2003) Pharmacological aspects of anticancer drug-induced emesis with emphasis on serotonin release and vagal nerve activity. Pharmacol Ther 99(2):149–165PubMedCrossRef

Percie du Sert N, Rudd JA, Moss R, Andrews PL (2009) The delayed phase of cisplatin-induced emesis is mediated by the area postrema and not the abdominal visceral innervation in the ferret. Neurosci Lett 465(1):16–20PubMedCrossRef

10.

Percie du Sert N, Rudd JA, Apfel CC, Andrews PL (2010) Cisplatin-induced emesis: systematic review and meta-analysis of the ferret model and the effects of 5-HT(3) receptor antagonists. Cancer Chemother Pharmacol 67:667–686PubMedCentralPubMedCrossRef

11.

Gupta YK, Sharma SS (2002) Involvement of 5-HT1A and 5-HT2 receptor in cisplatin induced emesis in dogs. Indian J Physiol Pharmacol 46(4):463–467PubMed

12.

Sam TS, Cheng JT, Johnston KD, Kan KK, Ngan MP, Rudd JA, Wai MK, Yeung JH (2003) Action of 5-HT3 receptor antagonists and dexamethasone to modify cisplatin-induced emesis in Suncus murinus (house musk shrew). Eur J Pharmacol 472(1–2):135–145PubMedCrossRef

13.

De Jonghe BC, Horn CC (2009) Chemotherapy agent cisplatin induces 48 h Fos expression in the brain of a vomiting species, the house musk shrew (Suncus murinus). Am J Physiol Regul Integr Comp Physiol 296(4):R902–R911PubMedCentralPubMedCrossRef

14.

Horn CC, Henry S, Meyers K, Magnusson MS (2011) Behavioral patterns associated with chemotherapy-induced emesis: a potential signature for nausea in musk shrews. Front Neurosci 5:88PubMedCentralPubMedCrossRef

15.

Huang D, Meyers K, Henry S, De la Torre F, Horn CC (2011) Computerized detection and analysis of cancer chemotherapy-induced emesis in a small animal model, musk shrew. J Neurosci Methods 197(2):249–258PubMedCentralPubMedCrossRef

16.

Zeimet AG, Reimer D, Radl AC, Reinthaller A, Schauer C, Petru E, Concin N, Braun S, Marth C (2009) Pros and cons of intraperitoneal chemotherapy in the treatment of epithelial ovarian cancer. Anticancer Res 29(7):2803–2808PubMed

17.

Holzer P (2004) Tachykinins. Handbook of experimental pharmacology, vol 164. Springer, Berlin

18.

Qian QH, Yue W, Wang YX, Yang ZH, Liu ZT, Chen WH (2009) Gingerol inhibits cisplatin-induced vomiting by down regulating 5-hydroxytryptamine, dopamine and substance P expression in minks. Arch Pharm Res 32(4):565–573PubMedCrossRef

19.

Yao X, Panichpisal K, Kurtzman N, Nugent K (2007) Cisplatin nephrotoxicity: a review. Am J Med Sci 334(2):115–124PubMedCrossRef

20.

Wang CH (1994) Introduction: a new experimental animal, Suncus murinus. In: Saito H, Wang CH, Chen CY (eds) Proceeding of ROC-Japan Symposium on Suncus murinus: new experimental animal, its speciality and usefulness, Tainan, Taiwan, R.O.C. Chia Nan Junior College of Pharmacy Press (Chia Nan, Taiwan ROC)

21.

Temple JL (2004) The musk shrew (Suncus murinus): a model species for studies of nutritional regulation of reproduction. ILAR J 45(1):25–34PubMedCrossRef

22.

Colville H, Dzadony R, Kemp R, Stewart S, Zeh HJ 3rd, Bartlett DL, Holleran J, Schombert K, Kosovec JE, Egorin MJ, Beumer JH (2010) In vitro circuit stability of 5-fluorouracil and oxaliplatin in support of hyperthermic isolated hepatic perfusion. J Extra Corpor Technol 42(1):75–79PubMedCentralPubMed

23.

Watson RE Jr, Wiegand SJ, Clough RW, Hoffman GE (1986) Use of cryoprotectant to maintain long-term peptide immunoreactivity and tissue morphology. Peptides 7(1):155–159PubMedCrossRef

24.

Armstrong DM, Pickel VM, Joh TH, Reis DJ, Miller RJ (1981) Immunocytochemical localization of catecholamine synthesizing enzymes and neuropeptides in area postrema and medial nucleus tractus solitarius of rat brain. J Comp Neurol 196(3):505–517PubMedCrossRef

25.

Hokfelt T, Ljungdahl A, Terenius L, Elde R, Nilsson G (1977) Immunohistochemical analysis of peptide pathways possibly related to pain and analgesia: enkephalin and substance P. Proc Natl Acad Sci USA 74(7):3081–3085PubMedCentralPubMedCrossRef

26.

Barajon I, Bersani M, Quartu M, Del Fiacco M, Cavaletti G, Holst JJ, Tredici G (1996) Neuropeptides and morphological changes in cisplatin-induced dorsal root ganglion neuronopathy. Exp Neurol 138(1):93–104PubMedCrossRef

27.

Reagan-Shaw S, Nihal M, Ahmad N (2008) Dose translation from animal to human studies revisited. FASEB J 22(3):659–661PubMedCrossRef

28.

Horn CC, Kimball BA, Wang H, Kaus J, Dienel S, Nagy A, Gathright GR, Yates BJ, Andrews PLR (2013) Why can’t rodents vomit? A comparative behavioral, anatomical, and physiological study. PLoS ONE 8(4):e60537PubMedCentralPubMedCrossRef

29.

Nakashima M, Shibata S, Tokunaga Y, Fujita H, Anda T, Arizono K, Tomiyama N, Sasaki H, Ichikawa M (1997) In-vivo microdialysis study of the distribution of cisplatin into brain tumour tissue after intracarotid infusion in rats with 9L malignant glioma. J Pharm Pharmacol 49(8):777–780PubMedCrossRef

30.

Brown R, Foran J, Olin S, Robinson D (1994) Physiological parameter values for PBPK models. International Life Sciences Institute: Risk Science Institute, Washington, DC

31.

Ramirez-Camacho R, Fernandez DE, Verdaguer JM, Gomez MM, Trinidad A, Garcia-Berrocal JR, Corvillo MA (2008) Cisplatin-induced hearing loss does not correlate with intracellular platinum concentration. Acta Otolaryngol 128(5):505–509PubMedCrossRef

32.

Esteban-Fernandez D, Verdaguer JM, Ramirez-Camacho R, Palacios MA, Gomez-Gomez MM (2008) Accumulation, fractionation, and analysis of platinum in toxicologically affected tissues after cisplatin, oxaliplatin, and carboplatin administration. J Anal Toxicol 32(2):140–146PubMedCrossRef

33.

Johnsson A, Olsson C, Nygren O, Nilsson M, Seiving B, Cavallin-Stahl E (1995) Pharmacokinetics and tissue distribution of cisplatin in nude mice: platinum levels and cisplatin-DNA adducts. Cancer Chemother Pharmacol 37(1–2):23–31PubMedCrossRef

34.

Sakaeda T, Kadoyama K, Okuno Y (2011) Adverse event profiles of platinum agents: data mining of the public version of the FDA adverse event reporting system, AERS, and reproducibility of clinical observations. Int J Med Sci 8(6):487–491PubMedCentralPubMedCrossRef

35.

Boissonade FM, Davison JS, Egizii R, Lucier GE, Sharkey KA (1996) The dorsal vagal complex of the ferret: anatomical and immunohistochemical studies. Neurogastroenterol Motil 8(3):255–272PubMedCrossRef

36.

Choie DD, Longnecker DS, del Campo AA (1981) Acute and chronic cisplatin nephropathy in rats. Lab Invest 44(5):397–402PubMed

37.

Liu M, Chien CC, Burne-Taney M, Molls RR, Racusen LC, Colvin RB, Rabb H (2006) A pathophysiologic role for T lymphocytes in murine acute cisplatin nephrotoxicity. J Am Soc Nephrol 17(3):765–774PubMedCrossRef

38.

van Hennik MB, van der Vijgh WJ, Klein I, Elferink F, Vermorken JB, Winograd B, Pinedo HM (1987) Comparative pharmacokinetics of cisplatin and three analogues in mice and humans. Cancer Res 47(23):6297–6301PubMed

39.

Zamboni WC, Gervais AC, Egorin MJ, Schellens JH, Hamburger DR, Delauter BJ, Grim A, Zuhowski EG, Joseph E, Pluim D, Potter DM, Eiseman JL (2002) Inter- and intratumoral disposition of platinum in solid tumors after administration of cisplatin. Clin Cancer Res 8(9):2992–2999PubMed

40.

Kizu R, Higashi S, Kidani Y, Miyazaki M (1993) Pharmacokinetics of (1R,2R-diaminocyclohexane)oxalatoplatinum(II) in comparison with cisplatin following a single intravenous injection in rabbits. Cancer Chemother Pharmacol 31(6):475–480PubMedCrossRef

41.

Hardie EM, Page RL, Williams PL, Fischer WD (1991) Effect of time of cisplatin administration on its toxicity and pharmacokinetics in dogs. Am J Vet Res 52(11):1821–1825PubMed

42.

Jacobs SS, Fox E, Dennie C, Morgan LB, McCully CL, Balis FM (2005) Plasma and cerebrospinal fluid pharmacokinetics of intravenous oxaliplatin, cisplatin, and carboplatin in nonhuman primates. Clin Cancer Res 11(4):1669–1674PubMedCrossRef

43.

Urien S, Lokiec F (2004) Population pharmacokinetics of total and unbound plasma cisplatin in adult patients. Br J Clin Pharmacol 57(6):756–763PubMedCentralPubMedCrossRef

44.

Freireich EJ, Gehan EA, Rall DP, Schmidt LH, Skipper HE (1966) Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother Rep Part 1 50(4):219–244

45.

Sugiura Y, Kitoh J (1984) The median and lateral substantia gelatinosa in the cervical cord of the musk shrew (Suncus murinus) and its synaptic composition. Anat Embryol (Berl) 170(1):21–28CrossRef

Title: Plasma pharmacokinetics and tissue and brain distribution of cisplatin in musk shrews
Authors: Julie L. Eiseman
Jan H. Beumer
Lora H. Rigatti
Sandra Strychor
Kelly Meyers
Samuel Dienel
Charles C. Horn
Publication date: 01-01-2015
Publisher: Springer Berlin Heidelberg
Published in: Cancer Chemotherapy and Pharmacology / Issue 1/2015
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-014-2623-5

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2015

EGFR–TKI is effective regardless of treatment timing in pulmonary adenocarcinoma with EGFR mutation

A pharmacokinetic and pharmacodynamic investigation of Modufolin® compared to Isovorin® after single dose intravenous administration to patients with colon cancer: a randomized study

Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma

Association of ABCG2 polymorphism with clinical efficacy of imatinib in patients with gastrointestinal stromal tumor

Phase I trial of S-1 every other day in combination with gemcitabine/cisplatin for inoperable biliary tract cancer

Predictive factors for survival in stage IIIA N2 NSCLC patients treated with neoadjuvant CCRT followed by surgery

Keynote webinar | Spotlight on antibody–drug conjugates in cancer